Relationship between mean platelet volume and disease activation in ankylosing spondylitis

Year 2025, Volume: 3 Issue: 1, 3 - 6, 01.02.2025

Ozan Durmaz , Adnan Özkahraman , Nüket Bayram Kayar , Mehmet Ali Bilgili , Yusuf Kayar , Refik Demirtunç

https://doi.org/10.61845/agrimedical.1433061

Abstract

Aim: In our study, we aimed to find the relationship between the activity of Ankylosing Spondylitis (AS) disease and mean platelet volume (MPV) and examine the relationship between disease activity and other parameters (Hemoglobin (Hb), Hematocrit (Htc), platelet, ESR, CRP.
Material and Method: 180 patients with an average age of 33.8±10.3 years (age range:18-67) participated in the study (number of AS patients:99 F/M:38/61, number of healthy controls:81 F/M:32/49). Within the first 24 hours after arriving at the hospital, blood was taken for all patients, and hemogram examinations were performed. The files of patients with AS were examined retrospectively and groups with active and inactive AS were determined according to the BASDAI score. The healthy control group and the patient group with AS were compared in terms of parameters such as leukocyte, Hb, Htc, platelet, MPV, CRP and ESH.
Results: Patients with AS were shown to have significantly greater values of leukocytes, platelets, CRP, and ESR, and lower values of Hb, Hct, and MPV when compared to the control group (p<0,05). Furthermore, compared to the control group, inflammatory markers such as CRP and ESH were higher in the Active AS and inactive AS subgroups, but MPV and Hb Hct levels were significantly lower (p<0,05).
Conclusions: While inflammatory parameters were significantly higher in the AS patient group, MPV and Hb values were also shown to be lower. It was shown that the current parameters examined could be an inexpensive biomarker both in the diagnosis and treatment follow-up of AS. Larger controlled prospective research is nevertheless required on this topic.

Keywords

Ankylosing spondylitis, activation, Mean platelet volume.

Ankilozan spondilit’te ortalama trombosit hacmiyle hastalık aktivasyonunun ilişkisi

Abstract

Amaç: Çalışmamızda, Ankilozan Spondilit (AS) hastalığının aktivitesi ile ortalama trombosit hacmi OTH arasındaki ilişkiyi bulmak ve hastalık aktivitesi ile diğer parametrelerle (Hemoglobin (Hb), Hematokrit (Htc), platelet, ESH, CRP olan ilişkisini incelemeyi amaçladık.
Gereç ve yöntem: Çalışmaya ortalama yaşları 33,8 ± 10,3 yıl (yaş aralığı: 18-67) olan 180 katılımcı alındı (AS hasta sayısı: 99 K/E:38/61, sağlıklı kontrol sayısı: 81 K/E:32/49). Hastaneye geldikten sonraki ilk 24 saat içinde, tüm hastalarahemogram tetkiki yapıldı. AS’li hastaların dosyaları retrospektif olarak incelendi ve BASDAI skoruna göre aktif ve inaktif AS’li gruplar belirlendi. Sağlıklı kontrol grubu ve AS olan hasta grubu, lökosit, Hb, Htc, platelet, OTH, CRP ve ESH gibi parametreler açısından karşılaştırıldı.
Bulgular: AS’li hastalarda kontrol grubuna göre lökosit, platelet, CRP ve ESH değerlerinin anlamlı olarak daha yüksek, Hb, Hct ve OTH’nin daha düşük olduğu saptandı (p<0,05). Ayrıca AS'li hasta alt gruplarından hem Aktif AS hem de inaktif AS hasta grubunda kontrol grubuna göre CRP ve ESH gibi inflamatuar parametrelerin daha yüksek, buna karşılık Hb, Hct ve OTH değerinin anlamlı olarak daha düşük olduğu görüldü (p<0,05).
Sonuç: AS hasta grubunda inflamatuar parametreler, anlamlı olarak daha yüksek iken OTH ve Hb değerinin düşük olduğu gösterildi. Bakılan mevcut parametrelerin AS’nin gerek tanı, gerekse tedavi takibinde ucuz bir biyobelirteç olabileceği gösterildi. Ancak bu konuda daha geniş kontrollü prospektif çalışmalara gereksinim duyulmaktadır.

Keywords

Ankilozan spondilit, aktivasyon, Mean platelet volume.

Ethical Statement

20.05.2013 tarihli İstanbul Haydarpaşa Numune hastanesinden alınmıştır.

Supporting Institution

Yok

Thanks

Yok

References

• 1. Boudjani R, Challal S, Semerano L, Sigaux J. Impact of different types of exercise programs on ankylosing spondylitis: a systematic review and meta-analysis. Disabil Rehabil.2023;45(24):3989-4000.
• 2. Zhou E, Wu J, Zeng K, Wang M, Yin Y. Comparison of biologics and small-molecule drugs in axial spondyloarthritis: a systematic review and network meta-analysis. Front Pharmacol.2023;14:1226528-30.
• 3. He Q, Luo J, Chen J, et al. The validity and reliability of quality of life questionnaires in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and metaanalysis. Health Qual Life Outcomes. 2022;20(1):116-21.
• 4. Batlı P, Algert C, Chapman N, Neal B; Progress collaborative group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004; 35:622-6.
• 5. Gao L, Zhan Y, Hu X, Liao S. Platelet-lymphocyte ratio and lymphocyte-monocyte ratio in inflammatory bowel disease and disease activity: A systematic review and meta-analysis.Scott Med J. 2023;68(3):101-9.
• 6. Cole JL, Marzec UM, Gunthel CJ, et al. Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients. Blood 1998; 91:3239-46.
• 7. Koçer D, Sarıgüzel FM, Güler E, et al. Evaluation of MPV Value as an Inflammatory Marker in Patients with Ankylosing Spondylitis. Türk Klinik Biyokimya Derg 2014; 12(2):73-7.
• 8. Kumthekar A, Sanghavi N, Natu A, Danve A. How to Monitor Disease Activity of Axial Spondyloarthritis in Clinical Practice. Curr Rheumatol Rep. 2024; 24:1141-50.
• 9. Gran JT, Husby G. Epidemiology of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. Mosby, Philadelphia, 2003:1153-9.
• 10. Endler G, Klimesch A, Plassmann HS, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002;117:399-404.
• 11. Douda T, Bures J, Rejchrt S, Kopácová M, Pecka M, Malý J. Mean platelet volume (MPV) in Crohn's disease patients. Cas Lek Cesk. 2006;145(11):870-3.
• 12. Noris P, Melazzini F, Balduini CL. New roles for mean platelet volume measurement in the clinical practice? Platelets. 2016;27:607-12.
• 13. Järemo P, Sandberg-Gertzen H. Platelet density and size in inflammatory bowel disease. Thromb Haemost. 1996;75(4):560-1.
• 14. Cassano V, Armentaro G, Iembo D, et al. Mean platelet volume (MPV) as new marker of diabetic macrovascular complications in patients with different glucose homeostasis: Platelets in cardiovascular risk. Cardiovasc Diabetol. 2024;23(1):89-92.
• 15. Burstein SA, Downs T, Friese P, et al. Thrombocytopoiesis in normal and sublethally irradiated dogs: response to human inteleukin-6. Blood 1992;80:420-8.
• 16. Debili N, Masse JM, Katz A, Guichard J, Breton- Gorius J. Effects of the recombinant hematopoietic growth factors IL-3, IL-6, stem cell factor and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. Blood 1993;82:84-95.
• 17. Zhang Y, Liu H. Correlation between insulin resistance and the rate of neutrophilslymphocytes, monocytes-lymphocytes, platelets-lymphocytes in type 2 diabetic patients. BMC Endocr Disord. 2024;24(1):42-5.
• 18. Geropoulos G, Psarras K, Papaioannou M, et al. The Effectiveness of Adipose Tissue-Derived Mesenchymal Stem Cells Mixed with Platelet-Rich Plasma in the Healing of Inflammatory Bowel Anastomoses: A Pre-Clinical Study in Rats. J Pers Med. 2024;14(1):121-3.
• 19. Kisacik B, Tufan A, Akdogan A, et al. Mean platelet volume (OTH): As a inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 2008;75:291-4.
• 20. Yazıcı S, Yazıcı M, Erer B, et al. The platelet functions in patients with ankylosing spondylitis : informa healthcare 2009;14:126-31.